di-O-ethyl-DL-tartaric acid | 123529-99-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: di-O-ethyl-DL-tartaric acid
• 英文别名: Di-O-aethyl-traubensaeure；dl-α.α'-Diaethoxy-bernsteinsaeure；(2S,3S)-2,3-diethoxybutanedioic acid
• CAS: 123529-99-7；147030-21-5；147030-22-6；147126-02-1
• 化学式: C₈H₁₄O₆
• 分子量: 206.196
• InChiKey: AMSHPZWQWXOVTH-WDSKDSINSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  14
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  93.1
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  二-O-乙基-Lg-酒石酸二乙酯 在 氢氧化钾 作用下， 生成 di-O-ethyl-DL-tartaric acid
  参考文献：
  名称：

  Mylo, Chemische Berichte, 1911, vol. 44, p. 3214

  摘要：

  DOI：

文献信息

• COMPOUNDS FOR THE TREATMENT OF ADDICTION
  申请人：Cannizzaro Carina E.

  公开号：US20130005689A1

  公开（公告）日：2013-01-03

  Disclosed are novel compounds having the structure of Formula (I): which are useful for treating mammals for dependence upon substances of addiction, for example addiction to a dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and/or alcohol. Also disclosed are pharmaceutical compositions comprising a therapeutically effective amount of a compound of Formula (I) and methods of using the compounds of Formula (I) in the treatment of addiction to a dopamine-producing agent.

  揭示了具有以下结构的新化合物（I）的结构： 这些化合物对于治疗哺乳动物对成瘾物质的依赖很有用，例如对多巴胺产生剂（如可卡因、吗啡、安非他命、尼古丁和/或酒精）的依赖。还揭示了包含化合物（I）的治疗有效量的药物组合物，以及使用化合物（I）治疗对多巴胺产生剂成瘾的方法。
• CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS
  申请人：ReSet Therapeutics, Inc.

  公开号：US20150284362A1

  公开（公告）日：2015-10-08

  The subject matter herein is directed to carbazole-containing amide, carbamate, and urea derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula I wherein the variable R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , A, D, E, G, J, L, M, Q, a, and b are accordingly described. Also provided are pharmaceutical compositions containing the compounds of formula I to treat a Cry-mediated disease or disorder, such as diabetes, complications associated with diabetes, Cushing's syndrome, NASH, NAFLD, asthma, and COPD.

  本文涉及含有咔唑基的酰胺、碳酸酯和脲衍生物，以及其结构式I中的药用可接受盐或水合物，其中变量R1、R2、R3、R4、R5、R6、R7、A、D、E、G、J、L、M、Q、a和b分别描述。还提供了含有式I化合物的药物组合物，用于治疗Cry介导的疾病或紊乱，如糖尿病、与糖尿病相关的并发症、库欣综合征、NASH、NAFLD、哮喘和COPD。
• Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
  申请人：Rebiere Francois

  公开号：US20050222257A1

  公开（公告）日：2005-10-06

  The invention relates to a method for preparing a sulphoxide compound of formula (I) either as a single enantiomer or in an enantiomerically enriched form, comprising the steps of: a) contacting a pro-chiral sulphide of formula (II) with a metal chiral complex, a base and an oxidizing agent in an organic solvent; and optionally b) isolating the obtained sulphoxide of formula (I). wherein n, Y, R 1 , R 1a , R 2 and R 2a are as defined in claim 1.

  该发明涉及一种制备公式(I)的砜氧化物化合物的方法，该化合物可以是单对映体或对映富集形式，包括以下步骤：a)将公式(II)的原手性硫醚与金属手性配合物、碱和氧化剂在有机溶剂中接触；以及可选地b)分离得到的公式(I)的砜氧化物。其中n、Y、R1、R1a、R2和R2a如权利要求1所定义。
• [EN] NEW PROCESS FOR THE PREPARATION OF RACEMIC ([2S[2R*[R[R*]]]] and ([2R[2S*[S[S*]]]]-(±)- alpha,alpha' -[imino-bis(methylene)]bis[6-fluoro­chroman-2-methanol] AND ITS PURE [2S[2R*[R[R*]&<br/>[FR] NOUVEAU PROCEDE DE PREPARATION DE ([2S[2R*[R[R*]]]] ET ([2R[2S*[S[S*]]]]-(+/-)- 20040521US4654362AVAN LOMMEN GUY R E [BE], et al198703311528DA1DAJ. HENDRICKX ET AL.: "LOCATION OF THE OH FUNCTIONS IN HYDROXYLATED METABOLITES OF NEBIVOLOL", JOURNAL OF CHROMATOGRAPHY A, vol. 729, no. 1+2, 1996, GB, pages 341 - 354, XP002270638J. HENDRICKX ET AL.LOCATION OF THE OH FUNCTIONS IN HYDROXYLATED METABOLITES OF NEBIVOLOLJOURNAL OF CHROMATOGRAPHY AGB19967291+2341354353VA1,54,55A
  申请人：EGYT GYOGYSZERVEGYESZETI GYAR

  公开号：WO2004041805A1

  公开（公告）日：2004-05-21

  Process for the preparation of racemic ([2S[2R*[R[R*]]]]- and ([2R[2S*[S[S*]]]]-(±)- α,α' -[imino-bis(methylene)]bis[6-fluoro­chroman-2-methanol] of the compound of the formula (I) and its pure ([2S[2R*[R[R*]]]]- and ([2R[2S*[S[S*]]]]- enantiomer compounds characterized in that the products are prepared from 4-­fluoro-phenole or 4-fluoro-anisole via crystalline, optically active intermediates.

  用于制备化合物（I）的混合对映体（[2S[2R*[R[R*]]]]-和([2R[2S*[S[S*]]]]-(±)- α,α' -[亚胺-双(亚甲基)]双[6-氟基-色苷-2-甲醇]的过程及其纯度（[2S[2R*[R[R*]]]]-和([2R[2S*[S[S*]]]]-对映体化合物的特征在于所述产物是从4-氟苯酚或4-氟苯甲醚经过结晶的、具有光学活性的中间体制备而成。
• [EN] DEXLANSOPRAZOLE PROCESS AND POLYMORPHS<br/>[FR] PROCÉDÉ DE PRÉPARATION DU DEXLANSOPRAZOLE ET AUTRES FORMES POLYMORPHES
  申请人：REDDYS LAB LTD DR

  公开号：WO2009117489A1

  公开（公告）日：2009-09-24

  Processes for the preparation of dexlansoprazole, an amorphous form of dexlansoprazole, a solid dispersion of amorphous dexlansoprazole and a pharmaceutically acceptable carrier, and processes for their preparation. Also provided are crystalline compounds 2-[(R)-[(4-chloro-3-methyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole and 2-[(R)-[(4-nitro-3-methyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, and methods for their preparation.

  制备右旋雷贝拉唑、右旋雷贝拉唑非晶形态、非晶态右旋雷贝拉唑与药物可接受载体的固体分散体的工艺，并提供了晶体化合物2-[(R)-[(4-氯-3-甲基-2-吡啶基)甲基]亚砜基]-1H-苯并咪唑和2-[(R)-[(4-硝基-3-甲基-2-吡啶基)甲基]亚砜基]-1H-苯并咪唑以及它们的制备方法。